Shots:
- Natera has reported the publication of data on Signatera, a personalized MRD test for resected colorectal liver metastases (CRLM), in JAMA Oncology, with findings also presented at the ESMO GI 2026
- The analysis incl. 298 pts from the GALAXY trial, an observational arm of CIRCULATE-Japan, assessing outcomes by MRD status & adj. CT (ACT) use over a median 43mos. follow-up
- Signatera identified MRD-positive CRLM pts who derived significant DFS & OS benefit from ACT, while MRD-negative pts showed favorable outcomes without survival benefit. Post-surgical MRD positivity (2–10wks.) strongly predicted worse DFS and OS regardless of prior neoadj. CT
Ref: Businesswire | Image: Natera | Press Release
Related News: Natera Launches Zenith Genomics in the US to Diagnose Rare Diseases
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
